Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01168544
Other study ID # LTC 712-050710
Secondary ID
Status Completed
Phase Phase 3
First received July 22, 2010
Last updated January 3, 2013
Start date May 2011

Study information

Verified date January 2013
Source Rijnstate Hospital
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Vitamin D deficiency is common in older persons, in particular in residents of nursing homes. This is mainly explained by the fact that older persons do not often go outside in the sunshine. On top of that the capacity of the skin to synthesize provitamin D is decreased and dietary vitamin D intake is low. Vitamin D deficiency leads to osteoporosis, falls and fractures. To prevent morbidity and mortality due to falls and fractures it seems logical to supplement vit D in order to correct the deficiency. The advised daily dose of vit D supplementation is 800 IU. Several studies showed that with this dose the required serum 25(OH)D levels will not be reached.

primary objective of this study is:

- to investigate whether with a loading dose based on body weight and baseline serum 25(OH)D level more patients reach adequate serum 25(OH)D levels compared to 800 IU a day.

- to determine the best consolidation treatment.

Secondary objective

- is a loading dose based on body weight and baseline serum 25(OH)D level safe to use in residents of nursing homes.

- is there a relation between the increase in serum 25(OH)D level and muscle strength (handgrip strength).

- is there a relation between the increase in serum 25(OH)D level and mobility (2 minute walk test).

Study design:

Randomised trial with 3 study groups:

- Group 1a. loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy.

- Group 1b. loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy.

- Group 2. 800 IU vit D3/ dag.

Study population:

Vitamine D deficient residents of nursing homes, 65 years or older.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Long term indication for living in a residential home for the elderly

- Age > 65 years

- Vitamin D deficiency (serum 25- hydroxycholecholecalciferol (25(OH)D3 < 50 nmol/l)

- Informed Consent

Exclusion Criteria:

- Hypercalcemia (serum CA > 2.60 mmol/l)

- Life expectancy < 1/2 year

- Multivitamin use including > 400 IE vit D

- Non-functional dominant arm

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
loading dose Vitamin D and 50.000 IU vit D3/month
loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
loading dose and 25.000 IU vit D3/month
loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
Vitamin D 800 IU /day
800 IU vit D3/day

Locations

Country Name City State
Netherlands Alysis Zorggroep, verpleeghuis zevenaar Zevenaar Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Rijnstate Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients reaching an adequate serum 25(OH)D level (75-150 nmol/l)
Secondary Proportion of patients reaching a serum 25(OH)D level > 220 nmol/l
Secondary Handgrip strength
Secondary Distance achieved in a 2 minute walk test